The DOI matches its Crossref record, with a small difference in title or year; 15 of the 15 references it cites were found in a registry or an index.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain. METHODS: We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death, as assessed in a time-to-event analysis. RESULTS: Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the dapagliflozin group and in 610 of 3132 patients (19.5%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.92; P<0.001). Worsening heart failure occurred in 368 patients (11.8%) in the dapagliflozin group and in 455 patients (14.5%) in the placebo group (hazard ratio, 0.79; 95% CI, 0.69 to 0.91); cardiovascular death occurred in 231 patients (7.4%) and 261 patients (8.3%), respectively (hazard ratio, 0.88; 95% CI, 0.74 to 1.05). Total events and symptom burden were lower in the dapagliflozin group than in the placebo group. Results were similar among patients with a left ventricular ejection fraction of 60% or more and those with a left ventricular ejection fraction of less than 60%, and results were similar in prespecified subgroups, including patients with or without diabetes. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risk of DKA is increased in persons using SGLT2is, especially in those being treated with insulin (especially if there has been a recent reduction in their insulin dose) and/or those with acute illnesses and prolonged fasting.1049,1050”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1049]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) and DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), SGLT2 inhibition reduced the risk of cardiovascular death and worsening HF events by 18% to 21%4,5 and improved KCCQ-CSS by 1.5 to 2.3 points”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (302).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (290).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [290]
In the citing paper
“Sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary composite outcome of CV death and total HF hospitalization by 22% in those with an LVEF below or equal to the median of 57%.534”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“DELIVER recruited 6263 patients with heart failure with mildly reduced or preserved (>40%) ejection fraction including 3109 patients without diabetes.”
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“Since 2021, two placebo-controlled SGLT2 inhibitor trials (EMPA-KIDNEY and DELIVER) have studied a large number of people without diabetes.”
In the citing paper
“Approximately 44% of patients randomized to either dapaglifl ozin or placebo had type 2 diabetes, and results were consistent regardless of the presence of type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
In the citing paper
“The primary outcome of a composite of worsening heart failure, de fi ned as hospitalization or urgent visit for heart failure, or cardiovascular death was reduced by 18% in patients treated with dapagli fl ozin compared with placebo (HR 0.82 [95% CI 0.73 -0.92]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationCategorical Data Analysis Using the SAS System
Ziegel, E. R., Stokes, M., Davis, C., & Koch, G. (1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 2,034
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationSolomon, S. D., Claggett, B. L., Lewis, E. F., Desai, A. S., Anand, I. S., Sweitzer, N. K., O’Meara, E., Shah, S. J., McKinlay, S. M., Fleg, J. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv464 · Cited by 538
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,002
Jhund, P. S., Claggett, B. L., Talebi, A., Butt, J. H., Gasparyan, S. B., Wei, L., McCaw, Z. R., Wilderäng, U., Bengtsson, O., Desai, A. S., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.0711 · Cited by 34
Self-citationMyocardial Metabolism in Heart Failure with Preserved Ejection Fraction
Henry, J. A., Couch, L. S., & Rider, O. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051195 · Cited by 30
Savage, P., Watson, C., Coburn, J., Cox, B., Shahmohammadi, M., Grieve, D., & Dixon, L. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14993 · Cited by 30
Ferreira, J. P., Anker, S. D., Butler, J., Filippatos, G., Januzzi, J. L., Schueler, E., Panova‐Noeva, M., Wetzel, K., Prochaska, J. H., Pocock, S., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.503 · Cited by 31
Ostrominski, J. W., Lassen, M. C. H., Butt, J. H., Claggett, B. L., Anand, I. S., Desai, A. S., Jhund, P. S., Lam, C. S. P., Pfeffer, M. A., Pitt, B., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.012 · Cited by 34
Self-citationGalli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 41
Nakashima, M., Nakamura, K., Nishihara, T., Ichikawa, K., Nakayama, R., Takaya, Y., Toh, N., Akagi, S., Miyoshi, T., Akagi, T., et al. (2023) · Nutrients · doi:10.3390/nu15030748 · Cited by 35
Fu, E. L., Patorno, E., Everett, B. M., Vaduganathan, M., Solomon, S. D., Levin, R., Schneeweiß, S., & Desai, R. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad273 · Cited by 30
Self-citationWang, Y., Gao, T., Meng, C., Li, S., Bi, L., Geng, Y., & Zhang, P. (2022) · European journal of medical research · doi:10.1186/s40001-022-00945-z · Cited by 31
Diallo, A., Carlos‐Bolumbu, M., & Galtier, F. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02154-4 · Cited by 35
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction
Vardeny, O., Desai, A. S., Jhund, P. S., Fang, J. C.-T., Claggett, B. L., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M., Lam, C. S. P., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2023.5318 · Cited by 31
Self-citationDesai, N. R., Olewińska, E., Famulska, A., Rémuzat, C., François, C., & Folkerts, K. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10385-y · Cited by 36
Hammoud, R. A., Liu, Q., Dixon, S. B., Onerup, A., Mulrooney, D. A., Huang, I., Jefferies, J. L., Rhea, I. B., Ness, K. K., Ehrhardt, M. J., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00157-8 · Cited by 30
Kasperová, B. J., Mráz, M., Svoboda, P., Hlaváček, D., Kratochvílová, H., Módos, I., Vrzáčková, N., Ivák, P., Janovská, P., Kobets, T., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02298-9 · Cited by 31
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives
Mauriello, A., Ascrizzi, A., Roma, A. S., Molinari, R., Caturano, A., Imbalzano, E., D’Andrea, A., & Russo, V. (2024) · Antioxidants · doi:10.3390/antiox13070806 · Cited by 29
Pană, M.-A., Boulmpou, A., İleri, Ç., Manzi, G., Golino, M., Ostojic, M., Galimzhanov, A. M., Busnatu, Ș., Mega, S., & Perone, F. (2025) · Medicina · doi:10.3390/medicina61020211 · Cited by 35
Hypertensive heart disease in older patients: considerations for clinical practice
Camafort, M., Kasiakogias, A., Agabiti‐Rosei, E., Masi, S., Iliakis, P., Bénétos, A., Jeong, J., Lee, H., Muiesan, M. L., Sudano, I., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.12.034 · Cited by 31
Standardized Definitions of Changes in Kidney Function in Trials of Heart Failure
Lala, A., Coca, S. G., Feinman, J., HAMO, C. E., Fiuzat, M., Abraham, W. T., O’Connor, C. M., Lindenfeld, J., Januzzi, J. L., Cavagna, I., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.041 · Cited by 31
Coppi, F., Pagnoni, G., Grossule, F., Nassar, A., Maini, A., Masaracchia, G., Sbarra, F., Battigaglia, E., Maggio, E., Aschieri, D., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12060213 · Cited by 32
Pavlović, N., Todorović, P., Maglica, M., Kumrić, M., Vukojević, K., Pogorelić, Z., & Božić, J. (2025) · Biomolecules · doi:10.3390/biom15111572 · Cited by 31
Use of Glucose-Lowering Agents in Diabetes and CKD
Alicic, R. Z., Neumiller, J. J., Galindo, R. J., & Tuttle, K. R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.018 · Cited by 35
Moghaddam, N., Hawkins, N. M., McKelvie, R. S., Poon, S., Joncas, S. X., MacFadyen, J. R., Honos, G. N., Wang, J., Rojas‐Fernandez, C. H., Kok, M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.10.013 · Cited by 30
Packer, M. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2849 · Cited by 29
Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer
Hammoud, R. A., Mulrooney, D. A., Rhea, I. B., Yu, C. H., Johnson, J. N., Chow, E. J., Ehrhardt, M. J., Hudson, M. M., Ness, K. K., Armstrong, G. T., et al. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.12.008 · Cited by 30
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 29
Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
Rolski, F., & Ma̧czewski, M. (2025) · Pharmaceuticals · doi:10.3390/ph18030313 · Cited by 33
Akiyama, H., Nishimura, A., Morita, N., & Yajima, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111984 · Cited by 30
Butt, J. H., Lu, H. Y., Kondo, T., Bachus, E., de Boer, R. A., Inzucchi, S. E., Jhund, P. S., Kosiborod, M., Lam, C. S. P., Martínez, F. A., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3000 · Cited by 31
Self-citationVerma, S., Mudaliar, S. R., & Greasley, P. J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02652-5 · Cited by 28
Self-citationAzzo, J. D., Dib, M., Zagkos, L., Zhao, L., Wang, Z., Chang, C.-P., Ebert, C., Salman, O., Gan, S., Zamani, P. L., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.011146 · Cited by 26
Gharagozloo, K., Mehdizadeh, M., Heckman, G. A., Rose, R. A., Howlett, J. G., Howlett, S. E., & Nattel, S. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.006 · Cited by 32
Ilonze, O. J., Ebong, I., Guglin, M. E., Nair, A., Rich, J., McLaughlin, V., Tedford, R. J., & Mazimba, S. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.031 · Cited by 30
Jaiswal, V., Mashkoor, Y., Raj, N., Rajak, K., Jaiswal, A., & Fonarow, G. C. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.06.030 · Cited by 29
SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation
Schmidt, K., Schmidt, A., Groß, S., Just, A., Pfanne, A., Fuchs, M., Jordan, M., Mohr, E., Pich, A., Fiedler, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65410-9 · Cited by 29
Fletcher, R. A., Rockenschaub, P., Neuen, B. L., Walter, I. J., Conrad, N., Mizani, M. A., Bolton, T. R., Lawson, C. A., Tomlinson, C., Logothetis, S. B., et al. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00215-9 · Cited by 28
Self-citationPharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Shah, B. R., BAJAJ, H. S., Butalia, S., Dasgupta, K., Eurich, D. T., Jain, R., Leung, K., Mansell, K. D., & Simpson, S. H. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.002 · Cited by 32
Anti-senescence therapies: a new concept to address cardiovascular disease
Stojanović, S. D., Thum, T., & Bauersachs, J. K. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf030 · Cited by 32
Bozkurt, B., Rossignol, P., & Vassalotti, J. A. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3683 · Cited by 32
SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
Stielow, M., Fijałkowski, Ł., Alaburda, A., Grześk, G., Grześk, E., Nowaczyk, J., & Nowaczyk, A. (2025) · Molecules · doi:10.3390/molecules30153112 · Cited by 30
Aziri, B., Begić, E., Јаnkovic, S., Mladenović, Z., Stanetić, B., Kovačević-Preradović, T., Iglica, A., & Mujaković, A. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14355 · Cited by 30
Phenomics and Robust Multiomics Data for Cardiovascular Disease Subtyping
Maiorino, E., & Loscalzo, J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318892 · Cited by 34
Cai, A., Zheng, C., Qiu, J., Fonarow, G. C., Lip, G. Y. H., Feng, Y., & Wang, Z. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad223 · Cited by 27
Hahn, R. T., Lawlor, M. K., Davidson, C. J., Badhwar, V., Sannino, A., Spitzer, E., Lurz, P. C., Lindman, B. R., Topilsky, Y., Baron, S. J., et al. (2023) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2023.09.018 · Cited by 27
Menghoum, N., Badii, M. C., Deltombe, M., Lejeune, S., Roy, C., Vancraeynest, D., Pasquet, A., Gerber, B. L., Horman, S., Gruson, D., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14699 · Cited by 28
Doiron, J. E., Li, Z., Yu, X., LaPenna, K. B., Quiriarte, H. D., Allerton, T. D., Koul, K., Malek, A. J., Shah, S. J., Sharp, T. E., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032646 · Cited by 25
Self-citationLuca, M. D., Crisci, G., Armentaro, G., Cicco, S., Talerico, G., Bobbio, E., Lanzafame, L., Green, C. G., McLellan, A. G., Debiec, R., et al. (2023) · Life · doi:10.3390/life14010030 · Cited by 31
Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias
Jaiswal, V., Ang, S. P., Kumar, D., Deb, N., Jaiswal, A., Joshi, A., NASIR, Y. M., Bandyopadhyay, D., Michos, E. D., Benjamin, E. J., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101615 · Cited by 26
Crispino, S. P., Segreti, A., Nafisio, V., Valente, D., Crisci, F., Ferro, A., Cavallari, I., Nusca, A., Ussia, G. P., & Grigioni, F. (2025) · Biomedicines · doi:10.3390/biomedicines13030608 · Cited by 32
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 35
Greco, A., Canale, M. L., Quagliariello, V., Oliva, S., Tedeschi, A., Inno, A., Biasio, M. D., Bisceglia, I., Tarantini, L., Maurea, N., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104780 · Cited by 28
Heart Failure With Improved Ejection Fraction
Riccardi, M., Pabón, M. A., Bhatt, A. S., Savarese, G., Metra, M., Volterrani, M., Lombardi, C., Vaduganathan, M., Solomon, S. D., Vardeny, O., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.544 · Cited by 29
Self-citationEffects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria
Staplin, N., Roddick, A., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Docherty, K. F., Fletcher, R. A., Inzucchi, S. E., et al. (2025) · JAMA · doi:10.1001/jama.2025.20835 · Cited by 35
Self-citationCardio-sarcopenia: A syndrome of concern in aging
Loh, D. R., Tan, R., Lim, W. S., & Koh, A. S.-M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1027466 · Cited by 25
Khedagi, A. M., Hoke, C., Kelsey, M. D., Coviello, A. D., Jones, W. S., Jackson, L. R., Patel, M. R., McGarrah, R. W., Pagidipati, N. J., & Shah, N. P. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100477 · Cited by 28
Transcatheter Left Ventricular Restoration in Patients With Heart Failure
Hamid, N. B., Jorde, U. P., Reisman, M., Latib, A., Lim, D. S., Joseph, S. M., Кurlianskaya, A., Polonetsky, O., Neužil, P., Reddy, V. Y., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.03.003 · Cited by 26
Marcos, M. C., de la Espriella, R., Ordás, J. G., Llàcer, P., Pomares, A., Fort, A., de Antonio, I. P., Méndez, A. B., Blázquez‐Bermejo, Z., Pérez, P. C., et al. (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.05.003 · Cited by 28
Residual Risk in Heart Failure and the Need for Simultaneous Implementation and Innovation
Fatima, K., Butler, J., & Fonarow, G. C. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3005 · Cited by 27
Bulhões, E., Antunes, V., Mazetto, R. A. S. V., Defante, M. L. R., Garcia, A. C., & Guida, C. M. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.04.058 · Cited by 29
Formiga, F., Núñez, J. E., Moraga, M. J. C., Marcos, M. C., Egocheaga, M. I., García‐Prieto, C. F., Trueba-Sáiz, Á., Gilarranz, A. M., & Rodríguez, J. M. F. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10360-z · Cited by 28
Greene, S. J., Butler, J., & Kosiborod, M. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.04.019 · Cited by 28
Self-citationSafety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis—A Clinical Feasibility Study
Steinhardt, M., Cejka, V., Chen, M., Bäuerlein, S., Schäfer, J. M., Adrah, A., Ihne-Schubert, S. M., Papagianni, A. E., Kortüm, K. M., Morbach, C., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010283 · Cited by 24
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 27
Self-citationKondo, T., Campbell, R. T., Jhund, P. S., Anand, I. S., Carson, P. E., Lam, C. S. P., Shah, S. J., Vaduganathan, M., Zannad, F. M., Zile, M. R., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.027 · Cited by 33
Self-citationEmerging opportunities to target inflammation: myocardial infarction and type 2 diabetes
Kufazvinei, T. T. J., Chai, J., Boden, K. A., Channon, K. M., & Choudhury, R. P. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae142 · Cited by 27
Towards Metabolomic-Based Precision Approaches for Classifying and Treating Heart Failure
Hahn, V. S., Selvaraj, S., Sharma, K., & Shah, S. H. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.04.008 · Cited by 26
Self-citationKittleson, M. M., Breathett, K. K., Ziaeian, B., Aguilar, D. A., Blumer, V. L., Bozkurt, B., Diekemper, R. L., Dorsch, M. P., Heidenreich, P. A., Jurgens, C. Y., et al. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000132 · Cited by 29
Magurno, M., Cassano, V., Maruca, F., Pastura, C. A., Divino, M., Fazio, F., Severini, G., Clausi, E., Armentaro, G., Miceli, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168811 · Cited by 25
Khadke, S., Kumar, A., Bhatti, A. W., Dani, S. S., Al-Kindi, S. G., Nasir, K., Virani, S. S., Upadhyay, J., Garcia-Banigan, D. C., Abraham, S., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.10.448 · Cited by 27
Self-citationLiang, I.-C., Chang, H.-H., Lai, Y.-J., Chan, C.-M., Sung, C.-H., Pu, C., Chang, D., Ho, C.-C., & Hung, C. (2025) · Medicina · doi:10.3390/medicina61020202 · Cited by 25
Ferreira, J. P., Vasques‐Nóvoa, F., Saraiva, F. A., Oliveira, A., Almeida, J., Batista, A. B., Barbosa, A., Ferreira, A. F., Costa, C., Diaz, S. O., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.05.033 · Cited by 30
Theofilis, P., Oikonomou, E. K., Tsioufis, K. P., & Tousoulis, D. (2023) · Life · doi:10.3390/life13020497 · Cited by 28
Peikert, A., Goyal, P., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Miao, Z. M., Vardeny, O., Kosiborod, M., Desai, A. S., Jhund, P. S., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.05.014 · Cited by 28
Self-citationDapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity
Ulusan, S. (2023) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2023.2825 · Cited by 25
Арманович, А. А., Sheibani, M., Вачиковна, П. Н., Mkrtchyan, L., Yeranosyan, H., Aznauryan, A., Sahakyan, K., Fogacci, F., Cicero, A. F. G., Shafie, D., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131331 · Cited by 25
Groenewegen, A., Zwartkruis, V. W., Rienstra, M., Zuithoff, N. P. A., Hollander, M., Koffijberg, H., Wolcherink, M. J. O., Cramer, M. J., van der Schouw, Y. T., Hoes, A. W., et al. (2023) · The Lancet Public Health · doi:10.1016/s2468-2667(23)00269-4 · Cited by 30
Verma, R., Dhingra, N. K., & Connelly, K. A. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001113 · Cited by 24
Chiang, C., Hung, C., Wu, Y., Lin, T., Ueng, K., Sung, S., Wu, C., Chao, T., Lin, H., Lin, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20230301a · Cited by 24
Self-citationChapter 1: The Burden of Heart Failure
Pratley, R. E., Guan, X., Moro, R. J., & do Lago, R. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.04.018 · Cited by 26
Bhanushali, K. B., Asnani, H., Nair, A. V., Ganatra, S., & Dani, S. S. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102664 · Cited by 28
Abdin, A., Wilkinson, C., Aktaa, S., Böhm, M., Polovina, M. M., Rosano, G. M. C., Lainščak, M., Lund, L. H., McDonagh, T. A., Metra, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3376 · Cited by 23
HFSA Scientific Statement: Update on Device Based Therapies in Heart Failure
Estep, J. D., Salah, H. M., Kapadia, S. R., Burkhoff, D., Lala, A., Butler, J., Hall, S. A., & Fudim, M. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.07.007 · Cited by 27
Chimura, M., Petrie, M. C., Schou, M., Martínez, F. A., Henderson, A. D., Claggett, B. L., Desai, A. S., Kolkhof, P., Viswanathan, P., Lage, A. Z., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012437 · Cited by 26
Self-citationNeuroimmune cross-talk in heart failure
Montuoro, S., Gentile, F., & Giannoni, A. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae236 · Cited by 25
Systolic Blood Pressure and Pulse Pressure in Heart Failure
Lu, H. Y., Kondo, T., Claggett, B. L., Vaduganathan, M., Neuen, B. L., Beldhuis, I. E., Jhund, P. S., Causland, F. R. M., Anand, I. S., Pfeffer, M. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.007 · Cited by 32
Self-citationSGLT2 inhibitors as a novel senotherapeutic approach
Yeşilyurt, Z. E., Qi, C., Wang, Y.-C., Simm, A., Deelen, L., Gasim, A. H. A., Lewis, F., & Ellison, G. M. (2025) · npj Aging · doi:10.1038/s41514-025-00227-y · Cited by 28
Finerenone in Heart Failure With Improved Ejection Fraction
Pabón, M. A., Vardeny, O., Vaduganathan, M., Desai, A. S., Claggett, B. L., Kulac, I. J., Jhund, P. S., Lam, C. S. P., Senni, M., Shah, S. J., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.1101 · Cited by 28
Self-citationYoo, T. T., Baek, I. H., Stoletniy, L. N., Hilliard, A. A., Sakr, A. E., & Doycheva, D. M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02777-7 · Cited by 24
Finerenone According to Frailty in Heart Failure
Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Chiang, C., Linssen, G. C. M., Saldarriaga, C., Saraiva, J. F. K., Sato, N., Schou, M., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.1775 · Cited by 27
Self-citationImpact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study
Albulushi, A., Askari, K., Al-Abedi, A. M., Al-Kulaibi, M. A., Hasan, M. S., Hosseini, Z., Al-Rahman, M. T., Tanoh, D. B., Hasan, A. S., Al-Helli, Y., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02834-7 · Cited by 27
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 29
Talha, K. M., Butler, J., Greene, S. J., Aggarwal, R., Anker, S. D., Claggett, B. L., Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., & Fonarow, G. C. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4348 · Cited by 25
Self-citationPotential Global Impact of Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure
Talha, K. M., Butler, J., Greene, S. J., Aggarwal, R., Anker, S. D., Claggett, B. L., Docherty, K. F., Solomon, S. D., McMurray, J. J. V., Januzzi, J. L., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2864 · Cited by 23
Self-citationBhatt, A. S., Kosiborod, M., Vaduganathan, M., Claggett, B. L., Miao, Z. M., Kulac, I. J., Lam, C. S. P., Hernandez, A. F., Martínez, F. A., Inzucchi, S. E., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2909 · Cited by 31
Self-citationShi, Y., Dong, G., & Guo, M. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.724 · Cited by 28
Triposkiadis, F. K., Sarafidis, P. A., Briasoulis, Α., Magouliotis, D. E., Athanasiou, T., Skoularigis, J. S., & Xanthopoulos, A. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155090 · Cited by 27
Lim, J., Kwak, S., Choi, Y., Rhee, T., Park, C. S., Kim, B., Han, K., Lee, H., Park, J., Kim, Y.-J., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030552 · Cited by 28
Poledniczek, M., Neumayer, C., Kopp, C. W., Schlager, O., Gremmel, T., Józkowicz, A., Gschwandtner, M. E., Koppensteiner, R., & Wadowski, P. P. (2023) · Biomedicines · doi:10.3390/biomedicines11082284 · Cited by 26
Sex Differences in the Development of Anthracycline-Associated Heart Failure
Diaz, A. N. R., Hurtado, G. P., Manzano, A. A., Keyes, M. J., Turissini, C., Choudhary, A., Curtin, C., Dommaraju, S., Warack, S., Strom, J. B., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.10.477 · Cited by 23
Daprodustat and Heart Failure in CKD
Cunningham, J. W., Claggett, B. L., Lópes, R. D., McMurray, J. J. V., Perkovic, V., Carroll, K., Hiemstra, T. F., Khavandi, K., Lukas, M. A., Ranganathan, P. R., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000321 · Cited by 24
Self-citationKittleson, M. M., Breathett, K. K., Ziaeian, B., Aguilar, D. A., Blumer, V. L., Bozkurt, B., Diekemper, R. L., Dorsch, M. P., Heidenreich, P. A., Jurgens, C. Y., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.014 · Cited by 27
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., Fang, J. C., Alcocer-Gamba, M. A., Al Habeeb, W., Han, Y., Cabrera Honorio, J. W., Janssens, S. P., Katova, T., Kitakaze, M., Merkely, B., O’Meara, E., Saraiva, J. F. K., Tereshchenko, S. N., Thierer, J., Vaduganathan, M., Vardeny, O., Verma, S., Pham, V. N., Wilderäng, U., Zaozerska, N., Bachus, E., Lindholm, D., Petersson, M., & Langkilde, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., B.C., A.S.D., M.V.); the British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom (J.J.V.M., P.S.J.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (R.A.B., C.S.P.L.), and Haga Teaching Hospital, the Hague (C.J.W.B.) — both in the Netherlands; the University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (A.F.H.); Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (M.N.K.); National Heart Center Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); National University of Cordoba, Cordoba (F.M.), and Jefe de Unidad de Insuficiencia Cardíaca, Centro de Educación Médica e Investigaciones Clínicas Norbert...
- Northwestern University (US)
- Semmelweis University (HU)
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Claggett, Brian
- de Boer, Rudolf A.
- DeMets, David
- Hernandez, Adrian F.
- Inzucchi, Silvio E.
- Kosiborod, Mikhail N.
- Lam, Carolyn S.P.
- Shah, Sanjiv J.
- Desai, Akshay S.
- Jhund, Pardeep S.
- Chiang, Chern-En
- Dobreanu, Dan
- Fang, James C.
- Alcocer-Gamba, Marco Antonio
- Han, Yaling
- Janssens, Stefan P.
- Kitakaze, Masafumi
- Merkely, Béla
- O’Meara, Eileen
- Tereshchenko, Sergey N.
- Thierer, Jorge
- Vaduganathan, Muthiah
- Vardeny, Orly
- Verma, Subodh
- Pham, Vinh Nguyen
- Wilderäng, Ulrica
- Bachus, Erasmus
- Lindholm, Daniel
- Petersson, Magnus
- Langkilde, Anna Maria
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-09-22
- Volume
- 387
- Issue
- 12
- Pages
- 1089-1098
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4293354639
- Cited by
- 2,884
- References
- 15
- Citations by year
- 2026: 635 · 2025: 716 · 2024: 714 · 2023: 673 · 2022: 139
- FWCI
- 390.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Lirias (KU Leuven) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- dapagliflozin, SGLT2 inhibitors, heart failure, preserved ejection fraction, mildly reduced ejection fraction, heart failure hospitalization, cardiovascular mortality, left ventricular ejection fraction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Heart Failure, Humans, Stroke Volume, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
